Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05322343
Other study ID # CHUBX 2020/34
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 22, 2022
Est. completion date September 21, 2025

Study information

Verified date October 2023
Source University Hospital, Bordeaux
Contact Cécilia SAMIERI, Dr
Phone 5 57 57 45 15
Email cecilia.samieri@u-bordeaux.fr
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

B cube is a new generation cohort to study the determinants and natural history of brain aging, using molecular epidemiology, in a representative sample (N=2000) of the general population from the age of 55 (the approximate age of onset of the first cognitive disorders and a target population particularly receptive to prevention messages). Special interest will be given to nutrition, a promising environmental exposure for prevention.


Description:

Cognitive aging and associated pathologies, primarily dementia and its main cause Alzheimer's disease, are a major public health issue. Because of the under-diagnosis of dementia in the population and the very long preclinical phase of these diseases, population-based cohorts are essential to better understand brain aging. With the PAQUID and 3-Cités cohorts, the Bordeaux Population Health Research Center (BPH) has been a world pioneer in population-based studies on aging and dementia, and has thus contributed greatly to a better understanding of age-realted brain diseases. As these cohorts are aging, and in view of the importance of studying the early stages of brain aging, it seems essential to continue our research efforts for the prevention of cognitive aging with the establishment of a new cohort of young seniors. In addition to the population-based design of the study, the representativeness of the cohort appears to be a crucial issue (since population-based cohorts depend on the voluntary participation of healthy individuals, unfavorable exposures and altered health states are often largely under-represented, which reduces the variability of exposures and events, leading to an underestimation of prevalences, a decrease in statistical power and a potential bias in the estimation of associations). Finally, the multifactorial nature of brain ageing pathologies now calls for the replacement of the reductionist approach of risk factors by a more holistic vision of the exposome (defined as all the environmental exposures with which an individual is confronted throughout the lifecourse). The development of an integrated approach of complex, high-dimensional, multi-omics biological data (genomics, transcriptomics, epigenomics, metabolomics, proteomics), applied to various biological matrices, is an indispensable tool to deep phenotyping and to the establishment of a new generation etiological epidemiological research framework in the field of brain aging pathologies. The Biobank and Brain health in Bordeaux cohort (B cube) will include the completion of a general questionnaire (during the V1 visit), a dietary survey (during the V1, V4 and V5 visits), a computerized cognitive battery (during the V1 visit), a collection of biological material (blood, urine, stool, saliva, hair, nails and nasopharyngeal swab) for the constitution of a biobank (during the V2 biobank visit, 2000 samples of blood, urine, hair, nails and 1000 samples expected for the other fluids/samples) An MRI will be performed in volunteers aged 55 to 70 years (during the V3 visit). Finally, a complementary visit by a medical specialist may be proposed to participants with cognitive disorders or Parkinson's syndrome.


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date September 21, 2025
Est. primary completion date September 21, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 55 Years to 80 Years
Eligibility Inclusion Criteria: For the main study: 1. live in Bordeaux metropolitan area, 2. be between 55 and 80 years old (included), 3. selected in terms of socioeconomic level, according to a sampling strategy by age groups and income categories representative of the general population between 55 and 80 years of age 4. be affiliated with the social security system, 5. agree to take a blood sample for the biobank. For the MRI sub-study: be between 55 and 70 years old (included). Inclusion criteria for the immune response substudy: be 70 years of age or older or participate in the MRI study; agree to take a supplemental blood sample for this substudy. Exclusion Criteria: For the main study: persons under guardianship (or more generally under protection), unable to give consent to participate. For the MRI sub-study: have a contraindication to MRI examination (pacemaker, a valve prosthesis or any other internal electrical/magnetic device; history of neurosurgery or aneurysm; claustrophobia; presence of metal fragments in the eyes, brain or spinal cord).

Study Design


Intervention

Other:
Questionnaires
Participants will complete a series of three questionnaires at the V1 visit (at home, by a trained interviewer): A general questionnaire, with collection of general health history and exposure data A nutritional survey (24-hour recall), that will be repeated by telephone twice at 3-month intervals, at the V4 and V5 visits. An evaluation of cognitive performance using a validated computerized battery (Cantab®), completed of neuropsychological tests to evaluate dementia syndromes, depressive symptoms and anxiety.
Fasting blood sampling.
In the morning, during the V2 visit by a nurse at the participant's home. Blood collection will include 8 blood tubes (volume approx.. 35.5 mL), plus 2 additional tubes for 500 participants accepting MRI, for a total volume of blood drawn of 41.5 mL for these participants. For the immunological substudy, a second sample will be taken at a distance (after 4 weeks) for 150 volunteer participants meeting the criteria.
Saliva collection and nasal or nasopharyngeal swab
On the day of the V2 visit, the nurse will collect a volume of saliva that has flowed spontaneously for 5 min in a sterile 40-mL polypropylene tube, and a nasal or nasopharyngeal swab using a specific kit.
Urine samples
During the V2 visit, the nurse will collect urine samples collected by the participant in the week preceding the appointment, using the equipment provided and kept in the refrigerator.
Hair and a tonenail (or hand nail) sampling
During the V2 visit, the nurse will collect some hair and a toenail sample from the participant, in a dedicated envelope
Nasal microbiota
Nasal or nasopharyngeal swab
Measurements
In addition to the samples, anthropometric measurements (weight, height,ead, waist, hip, calf and arm circumferences, subjective evaluation of body shape trajectories over the lifecourse), blood pressure, orthostatic hypotension, walking speed, grip strength, and hearing screening of sarcopenia and Parkinson's syndromes will also be collected by the nurse on the day of the V2 visit. Analyses may be performed on the biobank samples. These analyses will include metabolite assays (Metabolon®), and may include genotyping for research purposes (without searching for specific genes.
Neuroimaging
A multi-sequence MRI will be performed at the V3 visit. None of the sequences used will require contrast injection. The MRI sequences used will be: a 3D MPRAGE T1-weighted sequence, a T2-weighted sequence (FLAIR), a diffusion EPI sequence, a magnetization transfer sequence, and a resting state functional MRI BOLD sequence. The total duration of the MRI examination will be approximately 50 minutes. The MRI will be performed at the Bioimaging Institute on an imager dedicated to research activities (3T Prisma Siemens).During V3 visit, a measurement of skin autofluorescence of advanced glycation products will also be performed
Medical visit
For the participants with cognitive disorders (evaluated by the neuropsychologist during the V1 visit) or Parkinson's syndrome (evaluated by the nurse during the V2 visit),a complementary visit by a neurologist may be proposed in order to specify the etiology of these disorders and to establish a possible diagnosis and etiology.

Locations

Country Name City State
France University Hospital of Bordeaux Bordeaux

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants for whom samples are available in the biobank and nutritional and cognitive surveys have been completed. General questionnaire and a computerized cognitive battery. Inclusion visit
Primary Number of participants for whom samples are available in the biobank and nutritional and cognitive surveys have been completed. Collection of biological material for the constitution of a biobank week 1
Primary Number of participants for whom samples are available in the biobank and nutritional and cognitive surveys have been completed. An MRI will be performed in volunteers aged 55 to 70 years. week 2
Primary Number of participants for whom samples are available in the biobank and nutritional and cognitive surveys have been completed. Dietary survey week 12 and week 24
Secondary Biobank inventory of the following biological samples Week 1
Secondary Cognitive performance, assessed through: non-verbal cognition-Neuropsychological Cambridge Neuropsychological Test Automated Battery (CANTAB) Inclusion visit
Secondary Cognitive performance, assessed through: non-verbal cognition - Verbal fluency Isaacs' set test (IST) Inclusion visit
Secondary Cognitive performance, assessed through: non-verbal cognition -Dementia Clinical Dementia Rating scale-Sum of Boxes (CDR-SOB) Inclusion visit
Secondary Cognitive performance, assessed through: non-verbal cognition- Mental Mini Mental State Examination (MMSE) Inclusion visit
Secondary Assement anxiety and depressive symptomatology - Anxiety Spielberger State-Trait Anxiety Inventory (STAI) Inclusion visit
Secondary Assement anxiety and depressive symptomatology - Drepression Center for Epidemiological Studies-Drepression scale (CES-D). Inclusion visit
Secondary Nutrition and Lifestyle evaluated Eating habits :The average of 3 recalls of 24 hours at 3-month intervals week 12 and week 24
Secondary Study to the microbiota intestinal, nasal and salivary Heterogeneity and diversity. Week 1
Secondary Immunosenescence mechanism study Identification of mechanisms immunosenescence Week 1
Secondary Cognitive performance, assessed through: non-verbal cognition- Mental episodic memory: Free and Cued Selective Reminding test (FCSRT) (Grober & Buschke test in French) inclusion visit
Secondary Cognitive performance, assessed through: non-verbal cognition- Mental Executive functions: Trail Making tests A and B (TMTA and B) inclusion visit
Secondary Incapacity and dependance Estriction to mobility (Rosow and Breslow) inclusion visit
Secondary Incapacity and dependance Instrumental and basic activities of Daily Living (Lawton, Katz) inclusion visit
Secondary Incapacity and dependance Degree of dependency according to french health insurance system (AG.G.I.R) inclusion visit
Secondary Nutrition and Lifestyle evaluated Physical activity (International Physical Activity Questionnaire) week 12 and week 24
Secondary Nutrition and Lifestyle evaluated other lifestyle factors (smoking and alcohol intakes) week 12 and week 24
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05777044 - The Effect of Hatha Yoga on Mental Health N/A
Recruiting NCT04680611 - Severe Asthma, MepolizumaB and Affect: SAMBA Study
Recruiting NCT04977232 - Adjunctive Game Intervention for Anhedonia in MDD Patients N/A
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT03207828 - Testing Interventions for Patients With Fibromyalgia and Depression N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Completed NCT04476446 - An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives Phase 3
Recruiting NCT02783430 - Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease Phase 2/Phase 3
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT04598165 - Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support N/A
Completed NCT03457714 - Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
Recruiting NCT05956912 - Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
Completed NCT05588622 - Meru Health Program for Cancer Patients With Depression and Anxiety N/A
Recruiting NCT05234476 - Behavioral Activation Plus Savoring for University Students N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Enrolling by invitation NCT03276585 - Night in Japan Home Sleep Monitoring Study
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A